<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412581</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0487</org_study_id>
    <nct_id>NCT00412581</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I Safety Study of the Combination of Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      1. To determine the maximum tolerated dose (MTD) of intravenous DTIC during the first 2
      cycles (6 weeks) of treatment when administered in combination with a fixed dose of oral
      Lenalidomide in patients with metastatic malignant melanoma previously untreated with
      systemic chemotherapy.

      Secondary Objectives:

        1. To define the recommended Phase II doses of Lenalidomide and DTIC when administered as
           combination therapy.

        2. To evaluate the safety and toxicity profile of combination Lenalidomide plus DTIC.

        3. To evaluate the preliminary efficacy of combination Lenalidomide plus DTIC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lenalidomide is related to a drug called Thalidomide, which is not widely used because of
      certain side effects. Lenalidomide belongs to a family of drugs that work by acting on the
      body's immune system, so that it makes more &quot;anti-inflammatory&quot; cells. This type of cell is
      normally found in the body and is believed to help reduce the growth of cancer cells and slow
      down the production of new cancer cells.

      DTIC is an anti-cancer drug. It is designed to cause cancer cell death by creating DNA breaks
      in the nucleus of the cells.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests&quot;. These tests will help the doctor decide if you are eligible to take part in the
      study. You will be asked questions about your medical history, and you will have a complete
      physical exam, which will included measurements of your temperature, pulse, blood pressure,
      respiratory (breathing) rate, weight and height. You will be asked about any surgeries you
      have had and any medications you are taking. Your ability to perform daily activities will be
      checked through simple physical tests (such as walking or squeezing a ball). You will also
      have blood drawn (about 1 tablespoon) for routine tests and tests to measure your thyroid
      hormones.

      You will have an electrocardiogram (ECG - a test that measures the electrical activity of the
      heart). You will have a chest x-ray and CT scans of the chest, abdomen and pelvis (below the
      waist). You will be required to have a MRI or CT scan of the brain. If your doctor feels it
      is necessary, you may need CT scans of the head and neck or a bone scan. To perform the bone
      scan, a small dose of radioactive technetium is administered intravenously (IV--through a
      needle in your vein). The technetium will collect in the areas of bone involved with
      metastatic cancer to &quot;light up&quot; these areas on the bone scan. The results of these tests will
      show if you are eligible to participate in the study. Women who are able to have children
      must have a negative blood pregnancy test.

      If you are still eligible to take part in the study, you will begin study treatment. You will
      take Lenalidomide by mouth every day for 2 weeks, followed by 1 week of &quot;rest.&quot; This 21-day
      period is referred to as one &quot;study cycle.&quot; You should only take Lenalidomide on an empty
      stomach. You should fast for 1 hour before and after taking Lenalidomide.

      DTIC will be given by IV on Day 1 of every study cycle. Three dose levels of DTIC will be
      tested during this study. The first 3 participants will be given the first (lowest) dose
      level of DTIC. After the safety of this dose of DTIC is confirmed at the starting dose level,
      the next 3 to 6 participants will be given the second dose level of DTIC. After the safety of
      this new dose level is confirmed, the dose of DTIC will be increased to the third (highest)
      dose level tested in this study. When the highest DTIC dose is found that has the fewest side
      effects when given with Lenalidomide, 10 more patients will be treated at this best dose
      level. Patients on the lowest dose level will not have their doses changed once the highest
      well tolerated dose is found. Once a patient starts on a dose, it will not be increased.

      You will receive treatment with Lenalidomide and DTIC on an outpatient basis at UT M.D.
      Anderson Cancer Center. At the start of each 21-day study cycle, you will come in to the
      clinic to receive a 14-day supply of Lenalidomide, and you will receive your dose of DTIC by
      IV. You will be provided with a study drug diary each time you are given your supply of
      Lenalidomide, to write down any side effects you experience.

      During each study visit, you will have a physical exam (including measuring your weight), and
      your medical history will be recorded. Your doctor will ask you about any side effects you
      are experiencing. You should bring your study drug diary, any unused medication, and empty
      packages of medication to each study visit. Women who are able to have children will have a
      pregnancy test performed during the study visit at the beginning of each study cycle. You
      will have blood drawn (about 1 tablespoon) for routine tests. You will also repeat the
      performance status tests.

      During your study visit at the beginning of Cycle 3 (about 6 weeks after starting treatment),
      you will be checked to see if the disease is responding to treatment. You will have a chest
      x-ray and CT scans of the chest, abdomen and pelvis. If your doctor feels it is necessary,
      you will also have an EKG for the heart and MRI of the brain. These tests may be done more
      often if your doctor feels it is necessary.

      You will continue to receive treatment as long as the disease is shrinking or does not get
      worse, and the study doctor decides that it is safe to do so. You will be taken off study if
      the disease progresses or intolerable side effects occur.

      If you are taken off study for any reason, you will be scheduled for a final study visit. You
      will have a physical exam and will be checked for side effects related to the study
      treatment. You will have a chest x-ray, CT scans, an ECG, and possibly an MRI as well.

      You will have blood drawn (about 1 tablespoon) for routine tests. You will be asked about any
      new symptoms that you may have experienced after the treatment was stopped.

      This is an investigational study. DTIC has been approved by the FDA for the treatment of
      metastatic melanoma. The FDA has authorized Lenalidomide for use in research only. Up to 28
      participants will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To find out the highest safe dose of DTIC that can be given in combination with a steady dose of Lenalidomide, to patients with malignant melanoma that has spread to other parts of the body and has not been treated with chemotherapy.</measure>
    <time_frame>2.5 Years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide + Dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg by mouth daily for 2 weeks, followed by 1 week of rest.</description>
    <arm_group_label>Lenalidomide + Dacarbazine</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>600 mg/m^2 intravenously on Day 1 of every study cycle.</description>
    <arm_group_label>Lenalidomide + Dacarbazine</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following inclusion criteria to be eligible for
             enrollment into the study: Understand and voluntarily sign an informed consent
             document.

          -  Age &gt;/= 18 years at the time of signing Informed Consent.

          -  Be able to adhere to the study visit schedule and other protocol requirements.

          -  Histological documentation of malignant melanoma with evidence of metastatic disease.

          -  For the 10 patients enrolled at the MTD, at least one measurable lesion must be
             present.

          -  ECOG performance status of 0,1,2.

          -  Laboratory tests within these ranges: a) Absolute neutrophil count &gt;/=
             1,500/microliter b) Platelet count &gt;/= 100,000/microliter, c) Serum creatinine &lt;/= 1.5
             mg/dL, d) Total bilirubin &lt;/= 1.5 mg/dL, e) AST (SGOT)/ALT (SGPT) &lt;/= 2 x upper limit
             of normal (ULN)

          -  Females of childbearing potential (FCBP)â€  must agree to use two reliable forms of
             contraception simultaneously or to practice complete abstinence from heterosexual
             intercourse during the following time periods related to this study. FCBP must have
             two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting
             study drug. Male Subjects: Must agree to use a latex condom during sexual contact with
             females of childbearing potential while participating in the study and for at least 28
             days following discontinuation from the study even if he has undergone a successful
             vasectomy.

          -  All acute toxic effects (excluding alopecia) of any prior therapy must have resolved
             to &lt; or = to grade 1 (NCI CTCAE v3.0). (not listed in protocol synopsis)

          -  Patients must be able to take medications orally.

        Exclusion Criteria:

          -  The presence of any of the following will exclude a patient from study enrollment:
             Pregnant or lactating females.

          -  Any serious medical condition, including psychiatric illnesses that will prevent the
             patient from signing the informed consent or place the patient at an unacceptable risk
             if he/she participates in the study.

          -  Prior treatment with systemic chemotherapy. Patients who have received prior
             immunotherapy, including thalidomide, or radiotherapy remain eligible. Lesions within
             a prior field of radiation may only be used as indicator lesions if there has been
             evidence of disease progression at that site.

          -  Prior history of malignancies (except for basal cell or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix or breast) unless the patient has been free of
             the disease for at least 3 years.

          -  Use of thalidomide or biologic response modifier therapy within 14 days of Day 1,
             Cycle 1.

          -  Prior &gt;/= grade-2 allergic reaction to thalidomide.

          -  Prior desquamating rash while taking thalidomide.

          -  Any prior use of CC-5013.

          -  Concurrent use of any other anti-cancer agents.

          -  Radiation or surgical treatment of melanoma within 28 days of starting study
             treatment.

          -  Active infection.

          -  Central nervous system (CNS) metastases.

          -  Patients with &gt;/= grade-2 neuropathy.

          -  Patients with known HIV positivity or AIDS-related illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agop Y. Bedikian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Dacarbazine</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimid</keyword>
  <keyword>DTIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

